A global leader in innovation needs a very strong university system: Carolyn Stein
With early-stage cancer, researchers have to wait for years to see how a drug works. This creates a very strong incentive for pharmaceutical firms to work on late-stage drugs only, with one exception being hematological cancers which have very good biomarkers to show if a drug is effective, said Carolyn Stein.
Source: indiatimes.com